The ALS Association is happy to continue our tradition of supporting bright, young scientists in ALS research through our Milton Safenowitz Postdoctoral Fellowship Program. These awards encourage young scientists to enter and, importantly, to remain in the ALS field.
The ALS Association is committed to helping improve clinical trial design, in order to increase trial efficiency that will more quickly lead to effective therapeutics. We awarded Dr. David Ennist and colleagues at Origent Data Sciences, Inc. two grants to support research exploring how machine learning algorithms, a type of computational tool, can optimize clinical trial design. Dr. Ennist’s work, recently published in the journal Annals of Clinical Trial and Translational Neurology, looks closely at optimizing patient randomization into clinical trials.
On December 7, 2017, Calaneet Balas began her role as president and CEO for The ALS Association. This article is the first in a new monthly blog series called "Calaneet’s Corner." Each column will provide you with a mission update and let you hear directly from Calaneet. Our first column goes behind the scenes to get to know Calaneet.
Held March 20-21, the annual ALS Advocacy Fly-In was very successful, as The ALS Association’s executives, staff, and board members acted boldly to fight for a cure for ALS. On March 20, Fly-In attendees heard presentations from numerous speakers, including Mark Vieth from CRD Associates, Dr. Steve Landers from the Visiting Nurse Association Health Group, Inc., and leaders from The ALS Association’s Iowa and Greater Philadelphia chapters.
UPDATE: As of March 14, 2019, enrollment for the CENTAUR Phase II clinical trial has been completed. The CENTAUR phase II clinical drug trial, sponsored by Amylyx Pharmaceuticals and funded by ALS Ice Bucket Challenge donations, began an open-label extension, giving people with ALS who completed their trial period an opportunity to continue taking the drug, AMX0035.
People living with ALS eventually lose the ability to speak. That means that preserving channels of communication is an important component of enhancing quality of life. The ALS Association - DC/MD/VA Chapter took this to heart when they initiated The Esther Lerner Brenner ALS Assistive Technology Lab in Maryland, which is designed to help people living with ALS communicate effectively for as long as possible.
The ALS Association is happy to continue our tradition of supporting bright, young scientists in ALS research through our Milton Safenowitz Postdoctoral Fellowship Program. These awards encourage young scientists to enter and, importantly, to remain in the ALS field. Today, we sit down with Dr. Yue Li from Scripps Research Institute – Florida to learn about his important research project studying how specific RNA-protein interactions contribute to ALS disease.
The ALS Association is happy to continue our tradition of supporting bright, young scientists in ALS research through our Milton Safenowitz Postdoctoral Fellowship Program. These awards encourage young scientists to enter and, importantly, to remain in the ALS field. Today, we sit down with Dr. Meredith Corley from the University of California, San Diego to learn about her unique research project studying how specific RNA-protein interactions contribute to ALS disease.
We sat down with Dr. John Landers, professor of Neurology at the University of Massachusetts Medical School, to discuss the recent discovery of the newest ALS gene, KIF5A, made possible by The ALS Association funding through ALS Ice Bucket Challenge donations. Dr. Landers is the co-leader of the U.S. arm of Project MinE, which is the largest ALS whole-genome sequencing effort of its kind. The discovery findings were published in the journal Neuron.
Our beloved daughter, Carmen Schentrup, was taken from us on February 14, one of 17 victims of the mass shooting at Marjory Stoneman Douglas High School in Parkland, Fla. Her life was cut too short. For the last month, we have tried to make sense of the senseless, and we have grieved with the other families.